Lifesci Capital Forecasts Tourmaline Bio FY2024 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities researchers at Lifesci Capital issued their FY2024 earnings estimates for Tourmaline Bio in a note issued to investors on Monday, February 24th. Lifesci Capital analyst R. Katkhuda anticipates that the company will earn ($2.89) per share for the year. Lifesci Capital currently has a “Outperform” rating and a $58.00 target price on the stock. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Lifesci Capital also issued estimates for Tourmaline Bio’s Q4 2024 earnings at ($0.88) EPS.

Several other research analysts have also issued reports on TRML. BMO Capital Markets began coverage on Tourmaline Bio in a research report on Friday, December 6th. They set an “outperform” rating and a $50.00 target price for the company. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of Tourmaline Bio in a report on Wednesday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tourmaline Bio has an average rating of “Buy” and a consensus price target of $54.67.

Tourmaline Bio Trading Up 2.4 %

Shares of NASDAQ:TRML opened at $12.55 on Wednesday. Tourmaline Bio has a 12 month low of $11.87 and a 12 month high of $48.31. The company has a market capitalization of $321.82 million, a price-to-earnings ratio of -4.45 and a beta of 2.32. The firm’s 50-day moving average is $17.35 and its 200 day moving average is $20.92.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brooklyn Investment Group purchased a new position in shares of Tourmaline Bio during the fourth quarter valued at $32,000. Tower Research Capital LLC TRC grew its holdings in Tourmaline Bio by 297.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company’s stock worth $33,000 after acquiring an additional 1,232 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Tourmaline Bio during the 4th quarter valued at about $47,000. Virtus ETF Advisers LLC purchased a new position in Tourmaline Bio during the 4th quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Tourmaline Bio by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock valued at $127,000 after purchasing an additional 1,920 shares in the last quarter. Institutional investors own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.